Thompson Siegel & Walmsley LLC Has $5.28 Million Stake in IQVIA Holdings Inc. (NYSE:IQV)

Thompson Siegel & Walmsley LLC boosted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 21.9% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 22,292 shares of the medical research company’s stock after buying an additional 4,000 shares during the quarter. Thompson Siegel & Walmsley LLC’s holdings in IQVIA were worth $5,283,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in IQVIA in the third quarter valued at approximately $147,683,000. 1832 Asset Management L.P. grew its position in IQVIA by 472.3% during the second quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock worth $96,487,000 after buying an additional 376,595 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of IQVIA during the second quarter valued at approximately $70,610,000. Impax Asset Management Group plc raised its stake in shares of IQVIA by 19.3% in the 2nd quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock valued at $344,998,000 after buying an additional 264,555 shares in the last quarter. Finally, Canada Pension Plan Investment Board lifted its stake in IQVIA by 6.6% during the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock worth $719,634,000 after purchasing an additional 211,653 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Up 1.6 %

IQV stock opened at $197.57 on Friday. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The stock has a market capitalization of $35.86 billion, a P/E ratio of 25.93, a P/E/G ratio of 1.97 and a beta of 1.51. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The business has a 50-day moving average of $223.40 and a 200-day moving average of $227.35.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. BTIG Research reduced their target price on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Evercore ISI reduced their target price on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Barclays lowered their price target on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a report on Friday, November 1st. JPMorgan Chase & Co. decreased their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th. Finally, Argus upgraded IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. Four equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $256.50.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. This trade represents a 6.24 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.60% of the company’s stock.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.